Paragon Ventures Announces Sale of Keene Medical Products

Buyer: Adapt Health
Seller: Keene Medical Products
Date / Year: April 1, 2022
Sector: Respiratory, Home Medical Equipment
Keywords: Respiratory, Home Medical Equipment, Kurt Filliault, Keith Filliault, Steve Griggs

Enfield, NH – Keene Medical Products has been acquired in a strategic transaction with Adapt Health.  Keene is a respiratory-focused full service durable medical equipment business with five locations in New Hampshire and four in Vermont where the company’s 132 employees sell a variety of DME, with CPAP emerging as a prime category in recent years.  Founded in 1975 Keene has always been on the forefront of the sector as a local industry leader.

“We are grateful that so many people have placed their trust in our teams of professionals and in our products and services. We are proud of our reputation and to have been awarded an HME Excellence Award for Best Respiratory Provider” remarked Keene owner, Kurt Filiault.  Terms of the transaction were not disclosed.

Paragon Ventures acted at the exclusive merger and acquisition advisor to Keene Medical Products in this transaction. The transaction team was led by Scott Fife, Vice President of Paragon Ventures who commented “It was an honor to work with Kurt and Keith Filiault, and to represent such a long-standing family owned business.  Keene shares with Adapt Health a common mission and drive for excellence and superior service.”

About AdaptHealth Corp.
AdaptHealth is a leading provider of home healthcare equipment, medical supplies to the home and related services in the United States. AdaptHealth provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home, adapt to life and thrive. Product and services offerings include (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea, (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors and insulin pumps), (iii) home medical equipment (HME) to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME medical devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics.  AdaptHealth services beneficiaries of Medicare, Medicaid and commercial insurance payors. AdaptHealth services approximately 1.8 million patients annually in all 50 states through its network of 269 locations in 41 states. Learn more at www.adapthealth.com.

About Paragon Ventures

Paragon Ventures is the leading healthcare merger and acquisition advisory focused exclusively on strategic transactions for private mid-market healthcare companies.  Since 1994, Paragon Ventures has advised thousands of healthcare business owners and successfully closed over 300 transactions across the continuum of healthcare.

The M&A market for healthcare companies continues to strengthen in 2022 and ahead of the projected increases in US capital gains taxes and interest rates.  There is unprecedented capital in market and strong acquirer motivations for high quality healthcare companies.  Across the continuum of care, buyers and investors are looking for well established, profitable businesses and offering strong valuations and options for management. 

Do you know the current market value of your business? We do!  We are here to help you plan, prepare, explore and succeed in executing your strategic options.

Contact Paragon Ventures for more information.  

www.paragonventures.com

800-719-1555

Contact Us

Paragon Ventures - CONFIDENTIAL CONTACT REQUEST (Market Pulse)
Sending

Strive Medical Acquires Urology Business From US Medical Supply
Vistria Group & Excellere Partners Acquire SCA Pharmaceuticals